David A. Talan, MD, FACEP, FIDSA
TITLES:
Professor, David Geffen School of Medicine at UCLA
Chairman, Department of Emergency Medicine
Faculty, Division of Infectious Disease
Olive View-UCLA Medical Center
MEDICAL INTERESTS:
Infectious Disease
OTHER INTERESTS:
Mountain biking, Guitar, Travel, Politics
RECENT PUBLICATIONS:
- Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Osborne T, Trezciak S, Huang D, Stevens D, Talan DA. Consensus guidelines for the treatment of severe sepsis and septic shock in the emergency department. Ann Emerg Med 2006;48:28-54.
- Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA for The EMERGEncy ID NET Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74.
- Talan DA, Moran GJ, Abrahamian FA (eds). Infectious Disease Emergencies, Infectious Disease Clinics of North America. St. Louis, Missouri, Elsevier Saunders, 2008 (Vol.22, No. 1).
PERSONAL PROFILE:
Dr. Talan received his medical degree from the University of Illinois and completed his residencies (Internal and Emergency Medicine) and Infectious Diseases fellowship at the UCLA and its associated medical centers. He is board certified in Internal Medicine, Emergency Medicine, and Infectious Diseases. Currently, Dr. Talan is Chairman of the Department of Emergency Medicine and faculty in the Division of Infectious Diseases at Olive View-UCLA Medical Center, and Professor of Medicine in Residence at UCLA School of Medicine.
Dr. Talan serves on the editorial boards of the Annals of Emergency Medicine, Emergency Medicine News, and Pediatric Emergency Care and is a reviewer for Clinical Infectious Diseases, JAMA, and The Medical Letter. Dr. Talan has researched acute infectious diseases, including bites, rabies, tetanus, pyelonephritis, meningitis, sepsis, and MRSA skin and soft tissue infections and has in the New England Journal of Medicine and JAMA. He is principal investigator of a CDC-supported emergency department-based national sentinel network for research on emerging infectious diseases in the United States called EMERGEncy ID NET and of an NIH contract to study off patent antibiotics to treat skin and soft tissue infections caused by community-associated MRSA.
